Biolab helps organ transplant patients by introducing the Panel Reactive Antibodies test

As part of its continued efforts to revolutionize the field of diagnostic medicine and elevate the standards of healthcare, Biolab, the leading accredited diagnostic laboratories in the Kingdom, recently launched the Panel Reactive Antibodies (PRA) test - an advanced immunology test that determines the type and quantity of antibodies present in patients seeking organ transplants such as kidney transplant. The PRA test utilizes an advanced diagnostic approach that stands to substantially increase the chances of successful organ transplants, saving lives and costs in the process.

The PRA isolates the type and quantity of antibodies that could potentially influence the acceptance of a transplanted organ by a given patient. The test replaces an older testing methodology that was not capable of determining the type and quantity of present antibodies, which will in turn allow physicians to establish higher confidence when selecting potential donors once the results of the PRA test are combined with those of tissue typing and other diagnostic approaches.

Biolab is a pioneer in applying advances in medicine and science to laboratory testing, providing a broad range of medical diagnostic services that spans 700 tests, in addition to offering a wide array of medical, scientific and consultancy services in the fields of health and diagnostics. Leveraging on cutting-edge technology, high caliber staff and an extensive insurance and bank affiliate network, Biolab offers its patients an unparalleled premium experience, prioritizing reliability, accountability and convenience.